Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Enovix Corporation in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Enovix Corporation’s 10-Q, filed May 14, 2026.
- Filed
- May 13, 2026, 8:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001828318-26-000029
| Line item | Fiscal Quarters Ended / April 5,2026 | Fiscal Quarters Ended / March 30,2025 |
|---|---|---|
| Cost of revenue | 6,048 | 4,837 |
| Gross profit | 1,552 | 261 |
| Operating expenses: | ||
| Research and development | 26,528 | 25,929 |
| Selling, general and administrative | 18,919 | 16,892 |
| Total operating expenses | 45,447 | 42,821 |
| Loss from operations | (43,895) | (42,560) |
| Other income (expense): |
Item 1. Financial Statements (unaudited)
FAQ
- What is Enovix Corporation's R&D?
- Enovix Corporation (ENVX) reported R&D of $26.53M in Q1 2026.
- How has Enovix Corporation's R&D changed year-over-year?
- Enovix Corporation's R&D increased by 2.3% year-over-year, from $25.93M to $26.53M.
- What is the long-term trend for Enovix Corporation's R&D?
- Over 4 years (2021 to 2025), Enovix Corporation's R&D has grown at a 30.7% compound annual growth rate (CAGR), from $37.85M to $110.33M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Enovix Corporation's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude